Paul Lammers
Company: Triumvira Immunologics
Job title: President & CEO
Seminars:
Using the Natural TCR as a Strategy to Penetrate Solid Tumors 9:30 am
Demonstrate different structure and biology of TAC T cells compared to other T cell therapies Pursuit of TAC T cells in multiple solid tumor types Opportunity to develop TAC T cells as optimal Adoptive Cell TherapyRead more
day: Day Two
Panel Discussion: Exploring the Potential of Soluble TCR Therapies to Redirect and Activate T Cells 1:00 pm
How do we enhance receptor-target interactions to develop safe and efficacious soluble TCR products? Beyond survival benefit, how do we define the clinical response rate to determine success in phase 3 clinical trials? What are the lessons that we have taken from antibodies?Read more
day: Day Two
Panel Discussion: Optimizing Development of Combination Approaches to Overcome the Solid Tumor Microenvironment 10:30 am
Exploring how to train T cells to overcome immune defence and survive in the low-nutrient, acidic and hypoxic tumour microenvironment Utilizing anti-PD1 antibody fragments secreted from T-cells after tumor interaction to overcome the local suppressive environment Profiling metabolic TME immuno-suppressive mechanisms through use of novel technology platformsRead more
day: Day Two
Chairman’s Opening Remarks 9:25 am
day: Day Two